Advertisement

Topics

Pfizer's Xeljanz Is First JAK Positive in PsA But Challenges Ahead

08:50 EDT 20 Jun 2017 | SCRIP

Pfizer’s oral JAK inhibitor Xeljanz is set to lead the JAK inhibitors to market in psoriatic arthritis following positive Phase...

      

Related Stories

 

Original Article: Pfizer's Xeljanz Is First JAK Positive in PsA But Challenges Ahead

NEXT ARTICLE

More From BioPortfolio on "Pfizer's Xeljanz Is First JAK Positive in PsA But Challenges Ahead"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...